COMPRESSING DRUG DISCOVERY

Novo Nordisk just named its strategic AI partner — and it's Amazon.
Novo Nordisk and Amazon Web Services (AWS) have announced a strategic partnership to accelerate drug discovery and modernize Novo's operations through agentic AI and cloud technology, anchored by a new co-innovation hub in London where AWS engineers and Novo R&D teams now work side by side.

What's actually in the agreement:
→ AWS becomes Novo Nordisk's preferred cloud provider and strategic AI partner, combining Novo's chronic-disease therapeutic expertise with AWS's life-sciences infrastructure → The partnership uses Amazon Bio Discovery and Amazon Bedrock to identify drug targets, design therapies faster, and connect genomic, imaging, and clinical data — so early research findings can directly shape clinical trial design → Amazon Bedrock AgentCore will drive AI-agent-led efficiencies across Novo's broader operations → This builds on results already in hand: the existing collaboration has reduced clinical documentation time and given more than 25,000 Novo employees AI-driven productivity tools

The stated goal, in CEO Maziar Mike Doustdar words, is compressing "the path from drug target to first human dose" — and AWS CEO Matt Garman framed it the same way from his side: getting medicines to patients faster.
Worth noting the scope goes beyond R&D — Novo already works with Amazon Pharmacy, Amazon Ads, and Amazon One Medical, so this cloud/AI agreement sits inside a much broader Amazon relationship spanning discovery through to how medicines actually reach patients.

©Karthasis